These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10648414)

  • 1. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
    Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
    Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
    Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
    Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.
    Pollett JB; Trudel S; Stern D; Li ZH; Stewart AK
    Blood; 2002 Nov; 100(10):3819-21. PubMed ID: 12393593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
    Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
    Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
    Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
    Qian S; Somlo G; Zhou B; Zhu L; Mi S; Mo X; Cheung EM; Qiu W; Lin RJ; Rossi J; Holtz M; Chu P; Yen Y
    Oligonucleotides; 2005; 15(1):1-11. PubMed ID: 15788896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
    Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular study of the t(4;14) in multiple myeloma.
    Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
    Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
    Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
    Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
    Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
    Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
    Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
    Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
    Trudel S; Ely S; Farooqi Y; Affer M; Robbiani DF; Chesi M; Bergsagel PL
    Blood; 2004 May; 103(9):3521-8. PubMed ID: 14715624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma.
    Fracchiolla NS; Luminari S; Baldini L; Lombardi L; Maiolo AT; Neri A
    Blood; 1998 Oct; 92(8):2987-9. PubMed ID: 9763594
    [No Abstract]   [Full Text] [Related]  

  • 15. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
    Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
    Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
    Chesi M; Nardini E; Brents LA; Schröck E; Ried T; Kuehl WM; Bergsagel PL
    Nat Genet; 1997 Jul; 16(3):260-4. PubMed ID: 9207791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
    Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
    Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
    Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
    Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
    [No Abstract]   [Full Text] [Related]  

  • 20. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
    Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
    Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.